A comprehensive review of the 2026 semi-annual reports of A-share listed companies uncovers a notable trend: technological premiums are progressively supplanting scale effects as the primary driver influencing the profitability of these enterprises. In the context of a burgeoning demand for AI computing power, heightened investment anticipations for the power grid's '15th Five-Year Plan', and the swift internationalization of innovative pharmaceuticals, companies endowed with core technologies, enjoying patent advantages, and showcasing cost competitiveness across the entire product lifecycle are attaining superior gross profit margins and enhanced order acquisition prowess. Zhan Yubo, Deputy Director of the Institute of Economics at the Shanghai Academy of Social Sciences, emphasized that this transformation signifies that related industries are stepping into a novel phase of development, characterized by a paradigm shift in their growth rationale. This evolution will incentivize companies to bolster their R&D investments, steer the hard technology sector towards high-value-added domains, and establish a robust groundwork for the sustained progression of high-end manufacturing.